Key result
Doubled adiponectin links to ~2.2 mL/min/1.73m² greater eGFR decline in African American men.
Why the study?
Few studies have examined the relationship of adiponectin with kidney disease in an exclusively African American population.
Does elevated baseline serum adiponectin predict albuminuria and subsequent decline in eGFR in African Americans?
Cohort (n=5,301)
Does elevated baseline serum adiponectin predict albuminuria and subsequent decline in eGFR in African Americans?
Elevated baseline serum adiponectin is an independent predictor of albuminuria and subsequent eGFR decline in African American men, but not women.
Answers are grounded in this paper and cite their sources.
Associated with faster eGFR decline in African American men; leaves open causal role and clinical utility.
PURPOSE: Few studies to date have examined the relationship of adiponectin with kidney disease in an exclusively African American (AA) population. The purpose of this study was to determine whether serum adiponectin was an independent predictor of the presence of albuminuria or decline in estimated glomerular filtration rate (eGFR) in AA. METHODS: The study included 5,301 AA participants enrolled in the Jackson Heart Study (JHS), Exam 1 and 3 (2000-2013). The primary outcome measure was the decline in eGFR. Cross sectional analyses were used to assess the relationship between albuminuria and serum adiponectin. Longitudinal analyses were used to assess the relationship between eGFR decline and adiponectin. RESULTS: Nearly 2/3 of subjects were women (63.5%) and about half (52%) of the participants were middle aged (45-65 years). Mean eGFR was 94.15 (±SD 21.98) mL/min/1.73 m2 and 6.30% of subjects had eGFR < 60 mL/min/1.73 m2 Mean serum adiponectin levels were 5408.69 ng/mL (±SD 4,280.32 ng/mL) and women had higher serum adiponectin levels 6139.14 ng/mL (±SD 4553.57 ng/mL) than men 4148.91 ng/mL (±SD 3414.43 ng/mL) (p < 0.001). Analyses revealed positive correlation between adiponectin levels and albuminuria (P = 0.001), an association significant only in men. During a median duration of follow up of approximately 8 years, a higher baseline adiponectin was associated with a subsequent higher decline in eGFR. Due to the skewed distribution and to facilitate the interpretation of results, we transformed baseline Adiponectin values to log base 2. So a unit higher baseline Log based 2 Adiponectin indicates a level two times the lower value. And an African American man with twice the baseline value of adiponectin had a risk of 2.22 mL/min/1.73 m2 higher subsequent decline in GFR (95% CI: -3.72 to -0.73; P = 0.003) over the study period. This effect was not seen in women. On further subgroup analysis of those with a rapid kidney function decline (eGFR rate loss >3.5 mL/min/year), the correlation between adiponectin and eGFR became more prominent (4.7 mL/min/1.73 m2 decline in eGFR per 10 years) (P = 0.006). No association was seen between baseline adiponectin and progressive eGFR decline in subgroups of men without rapid kidney function decline. CONCLUSION: In AA men, elevated adiponectin level at baseline is an independent predictor of albuminuria and subsequent decline in eGFR.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2025) conducted a cohort in Kidney disease (albuminuria and eGFR decline) (n=5,301). Serum adiponectin was evaluated on Decline in eGFR (2.22 mL/min/1.73 m2 higher decline per log2 increase, 95% CI -3.72 to -0.73, p=0.003). In African American men, a two-fold higher baseline serum adiponectin level was associated with a 2.22 mL/min/1.73 m2 greater subsequent decline in eGFR (95% CI: -3.72 to -0.73; P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: